Description

cingal

The first and only authorized combination viscosupplement designed to give the advantages of a fast-acting steroid and cross-linked hyaluronic acid (HA) to successfully treat osteoarthritis (OA) symptoms is called Cingal®. It is a potent, first-of-its-kind therapy that combines the advantages of Anika’s exclusive HA formulation of Monovisc®, which has been shown to provide OA symptoms relief for up to six months, with the well-known steroid triamcinolone hexacetonide (TH), which is FDA-approved and helps reduce inflammation and provide additional short-term pain relief.1

With Cingal, patients with osteoarthritis pain ranging from mild to moderate can benefit from Anika’s unique HA formulation.

Key Features and Benefits: Cingal showed promise in its pivotal clinical trial from 2014 in terms of providing patients with knee OA with immediate and sustained pain alleviation.One steroid injection relieves pain quickly and temporarily within a few days.1 HA viscosupplement offers long-lasting pain alleviation that could continue for up to six months.1
Simple single-injection therapy
Extremely potent, non-animal source HA
robust safety profile for both first and subsequent injections